{"id":66920,"date":"2026-06-01T13:39:49","date_gmt":"2026-06-01T05:39:49","guid":{"rendered":"https:\/\/flcube.com\/?p=66920"},"modified":"2026-06-01T13:39:51","modified_gmt":"2026-06-01T05:39:51","slug":"nmpa-opens-2026-national-reimbursement-drug-list-application-window-with-revised-eligibility-criteria-and-price-controls","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66920","title":{"rendered":"NMPA Opens 2026 National Reimbursement Drug List Application Window with Revised Eligibility Criteria and Price Controls"},"content":{"rendered":"\n

China’s National Medical Products Administration (NMPA)<\/strong> has released the “2026 Adjustment Work Plan for the National Reimbursement Drug Lists for Basic Medical Insurance, Maternity Insurance, Work-Related Injury Insurance, and the Commercial Health Insurance Innovative Drug List<\/strong>,” opening the online application system from June 1\u201310, 2026<\/strong>. The comprehensive framework establishes detailed eligibility criteria for both new drug inclusion and existing drug renewal, while introducing stringent price warning mechanisms<\/strong> to control healthcare costs in the world’s second-largest pharmaceutical market.<\/p>\n\n\n\n

Regulatory Framework<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Program<\/strong><\/td>National Reimbursement Drug Lists (NRDL) 2026 Adjustment<\/td><\/tr>
Application Window<\/strong><\/td>June 1\u201310, 2026<\/td><\/tr>
Key Components<\/strong><\/td>Basic Medical Insurance, Maternity Insurance, Work-Related Injury Insurance, Commercial Health Insurance Innovative Drug List<\/td><\/tr>
Price Control Mechanism<\/strong><\/td>Yellow\/Red label warnings based on reimbursement standard multiples<\/td><\/tr>
Implementation Timeline<\/strong><\/td>Drugs must complete technical review by June 10, 2026; marketing approval required by July 3, 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Eligibility Criteria for New Drug Inclusion<\/h2>\n\n\n\n

The 2026 adjustment plan defines eight distinct pathways<\/strong> for out-of-list drugs to qualify for NRDL inclusion:<\/p>\n\n\n\n

    \n
  1. New generic name drugs<\/strong> approved or completing technical review between January 1, 2021 \u2013 June 10, 2026<\/strong><\/li>\n\n\n\n
  2. Significant indication changes<\/strong> for drugs approved during the same period with updated drug approval certificates<\/li>\n\n\n\n
  3. Conditional-to-regular approvals<\/strong> for new generic name drugs granted conditional approval after January 1, 2020, and converted to regular approval between January 1, 2023 \u2013 May 31, 2026<\/strong><\/li>\n\n\n\n
  4. National Essential Medicines List<\/strong> inclusions<\/li>\n\n\n\n
  5. Commercial Health Insurance Innovative Drug List (2025)<\/strong> inclusions<\/li>\n\n\n\n
  6. Encouraged Generic Drugs<\/strong> or Pediatric R&D Priority Drugs<\/strong> approved before June 10, 2026<\/li>\n\n\n\n
  7. Rare disease treatments<\/strong> approved or completing technical review before June 10, 2026<\/li>\n\n\n\n
  8. Previously negotiated drugs<\/strong> that lost coverage due to unsuccessful renewal, with new generic equivalents approved between January 1, 2021 \u2013 May 31, 2026<\/strong><\/li>\n<\/ol>\n\n\n\n

    Notably, drugs failing to complete technical review by June 10 but obtaining marketing approval before July 3 do not qualify<\/strong> for the 2026 cycle.<\/p>\n\n\n\n

    Renewal Requirements for Existing Drugs<\/h2>\n\n\n\n

    For drugs currently on the list seeking renewal or scope adjustment:<\/p>\n\n\n\n